#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Primary liver cancer is the sixth most prevalent cancer and the second leading cause of cancer mortality worldwide .
3-1	17-24	Primary	abstract[4]	new[4]	coref	3-5[5_4]
3-2	25-30	liver	object|abstract[4]	new|new[4]	coref	4-5
3-3	31-37	cancer	abstract[4]	new[4]	_	_
3-4	38-40	is	_	_	_	_
3-5	41-44	the	abstract[5]	giv[5]	coref	4-1[10_5]
3-6	45-50	sixth	abstract[5]	giv[5]	_	_
3-7	51-55	most	abstract[5]	giv[5]	_	_
3-8	56-65	prevalent	abstract[5]	giv[5]	_	_
3-9	66-72	cancer	abstract[5]	giv[5]	_	_
3-10	73-76	and	abstract[5]	giv[5]	_	_
3-11	77-80	the	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
3-12	81-87	second	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
3-13	88-95	leading	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
3-14	96-101	cause	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
3-15	102-104	of	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
3-16	105-111	cancer	abstract[5]|abstract[6]|object[8]	giv[5]|new[6]|new[8]	_	_
3-17	112-121	mortality	abstract[5]|abstract[6]|abstract|object[8]	giv[5]|new[6]|new|new[8]	_	_
3-18	122-131	worldwide	abstract[5]|abstract[6]|object[8]	giv[5]|new[6]|new[8]	_	_
3-19	132-133	.	_	_	_	_

#Text=The most common primary liver cancer is hepatocellular carcinoma ( HCC ) , which accounts for >85 % of all cases .
4-1	134-137	The	abstract[10]	giv[10]	coref	4-8[11_10]
4-2	138-142	most	abstract[10]	giv[10]	_	_
4-3	143-149	common	abstract[10]	giv[10]	_	_
4-4	150-157	primary	abstract[10]	giv[10]	_	_
4-5	158-163	liver	object|abstract[10]	giv|giv[10]	coref	6-11
4-6	164-170	cancer	abstract[10]	giv[10]	_	_
4-7	171-173	is	_	_	_	_
4-8	174-188	hepatocellular	abstract[11]	giv[11]	appos	4-11[0_11]
4-9	189-198	carcinoma	abstract[11]	giv[11]	_	_
4-10	199-200	(	_	_	_	_
4-11	201-204	HCC	abstract	giv	coref	5-1
4-12	205-206	)	_	_	_	_
4-13	207-208	,	_	_	_	_
4-14	209-214	which	_	_	_	_
4-15	215-223	accounts	_	_	_	_
4-16	224-227	for	_	_	_	_
4-17	228-231	>85	quantity[13]	new[13]	coref	7-9[33_13]
4-18	232-233	%	quantity[13]	new[13]	_	_
4-19	234-236	of	quantity[13]	new[13]	_	_
4-20	237-240	all	quantity[13]|abstract[14]	new[13]|new[14]	_	_
4-21	241-246	cases	quantity[13]|abstract[14]	new[13]|new[14]	_	_
4-22	247-248	.	_	_	_	_

#Text=HCC predominantly arises in the setting of cirrhosis associated with hepatitis B and C virus infections , alcohol abuse , non-alcoholic steatohepatitis and metabolic diseases .
5-1	249-252	HCC	abstract	giv	coref	6-2
5-2	253-266	predominantly	_	_	_	_
5-3	267-273	arises	_	_	_	_
5-4	274-276	in	_	_	_	_
5-5	277-280	the	abstract[16]	new[16]	_	_
5-6	281-288	setting	abstract[16]	new[16]	_	_
5-7	289-291	of	abstract[16]	new[16]	_	_
5-8	292-301	cirrhosis	abstract[16]|abstract	new[16]|new	_	_
5-9	302-312	associated	_	_	_	_
5-10	313-317	with	_	_	_	_
5-11	318-327	hepatitis	abstract|place[19]	new|new[19]	_	_
5-12	328-329	B	place[19]	new[19]	_	_
5-13	330-333	and	_	_	_	_
5-14	334-335	C	_	_	_	_
5-15	336-341	virus	abstract|event[21]	new|new[21]	_	_
5-16	342-352	infections	event[21]	new[21]	_	_
5-17	353-354	,	_	_	_	_
5-18	355-362	alcohol	event[22]	new[22]	_	_
5-19	363-368	abuse	event[22]	new[22]	_	_
5-20	369-370	,	_	_	_	_
5-21	371-384	non-alcoholic	abstract[23]	new[23]	_	_
5-22	385-400	steatohepatitis	abstract[23]	new[23]	_	_
5-23	401-404	and	_	_	_	_
5-24	405-414	metabolic	abstract[24]	new[24]	_	_
5-25	415-423	diseases	abstract[24]	new[24]	_	_
5-26	424-425	.	_	_	_	_

#Text=Early-stage HCC patients are often subjected to surgical resection and liver transplantation .
6-1	426-437	Early-stage	person[26]	new[26]	coref	8-28[51_26]
6-2	438-441	HCC	abstract|person[26]	giv|new[26]	coref	9-12
6-3	442-450	patients	person[26]	new[26]	_	_
6-4	451-454	are	_	_	_	_
6-5	455-460	often	_	_	_	_
6-6	461-470	subjected	_	_	_	_
6-7	471-473	to	_	_	_	_
6-8	474-482	surgical	event[27]	new[27]	coref	7-7[0_27]
6-9	483-492	resection	event[27]	new[27]	_	_
6-10	493-496	and	_	_	_	_
6-11	497-502	liver	object|event[29]	giv|new[29]	coref|coref|coref|coref	7-15[0_29]|8-37|7-15[0_29]|8-37
6-12	503-518	transplantation	event[29]	new[29]	_	_
6-13	519-520	.	_	_	_	_

#Text=However , 5-year recurrence rates after resection reach >70 % and the efficiency of transplantation is limited by organ shortage and technical issues .
7-1	521-528	However	_	_	_	_
7-2	529-530	,	_	_	_	_
7-3	531-537	5-year	abstract[31]	new[31]	coref	8-9[43_31]
7-4	538-548	recurrence	event|abstract[31]	new|new[31]	_	_
7-5	549-554	rates	abstract[31]	new[31]	_	_
7-6	555-560	after	_	_	_	_
7-7	561-570	resection	event	giv	_	_
7-8	571-576	reach	_	_	_	_
7-9	577-580	>70	quantity[33]|abstract[34]	giv[33]|new[34]	coref|coref|coref|coref	8-15[45_33]|8-15[46_34]|8-15[45_33]|8-15[46_34]
7-10	581-582	%	quantity[33]|abstract[34]	giv[33]|new[34]	_	_
7-11	583-586	and	abstract[34]	new[34]	_	_
7-12	587-590	the	abstract[34]|abstract[35]	new[34]|new[35]	_	_
7-13	591-601	efficiency	abstract[34]|abstract[35]	new[34]|new[35]	_	_
7-14	602-604	of	abstract[34]|abstract[35]	new[34]|new[35]	_	_
7-15	605-620	transplantation	abstract[34]|abstract[35]|event	new[34]|new[35]|giv	_	_
7-16	621-623	is	_	_	_	_
7-17	624-631	limited	_	_	_	_
7-18	632-634	by	_	_	_	_
7-19	635-640	organ	abstract|abstract[38]	new|new[38]	_	_
7-20	641-649	shortage	abstract[38]	new[38]	_	_
7-21	650-653	and	_	_	_	_
7-22	654-663	technical	abstract[39]	new[39]	_	_
7-23	664-670	issues	abstract[39]	new[39]	_	_
7-24	671-672	.	_	_	_	_

#Text=Although local ablation and transarterial chemoembolization respectively confer 5-year survival rates of 50 – 70 % and survival benefit of >6 months , they are confined to patients with single tumors or multinodular tumors with good liver reserve .
8-1	673-681	Although	_	_	_	_
8-2	682-687	local	abstract[40]	new[40]	_	_
8-3	688-696	ablation	abstract[40]	new[40]	_	_
8-4	697-700	and	_	_	_	_
8-5	701-714	transarterial	substance[41]	new[41]	_	_
8-6	715-732	chemoembolization	substance[41]	new[41]	_	_
8-7	733-745	respectively	_	_	_	_
8-8	746-752	confer	_	_	_	_
8-9	753-759	5-year	abstract[43]	giv[43]	_	_
8-10	760-768	survival	event|abstract[43]	new|giv[43]	coref	8-18
8-11	769-774	rates	abstract[43]	giv[43]	_	_
8-12	775-777	of	abstract[43]	giv[43]	_	_
8-13	778-780	50	abstract[43]|quantity	giv[43]|new	_	_
8-14	781-782	–	abstract[43]	giv[43]	_	_
8-15	783-785	70	abstract[43]|quantity[45]|abstract[46]	giv[43]|giv[45]|giv[46]	ana|coref|ana|coref	8-24[0_46]|13-19[98_45]|8-24[0_46]|13-19[98_45]
8-16	786-787	%	abstract[43]|quantity[45]|abstract[46]	giv[43]|giv[45]|giv[46]	_	_
8-17	788-791	and	abstract[43]|abstract[46]	giv[43]|giv[46]	_	_
8-18	792-800	survival	abstract[43]|abstract[46]|event|abstract[48]	giv[43]|giv[46]|giv|new[48]	coref|coref	11-14[73_0]|11-14[73_0]
8-19	801-808	benefit	abstract[43]|abstract[46]|abstract[48]	giv[43]|giv[46]|new[48]	_	_
8-20	809-811	of	abstract[43]|abstract[46]|abstract[48]	giv[43]|giv[46]|new[48]	_	_
8-21	812-814	>6	abstract[43]|abstract[46]|abstract[48]|time[49]	giv[43]|giv[46]|new[48]|new[49]	_	_
8-22	815-821	months	abstract[43]|abstract[46]|abstract[48]|time[49]	giv[43]|giv[46]|new[48]|new[49]	_	_
8-23	822-823	,	_	_	_	_
8-24	824-828	they	abstract	giv	_	_
8-25	829-832	are	_	_	_	_
8-26	833-841	confined	_	_	_	_
8-27	842-844	to	_	_	_	_
8-28	845-853	patients	person[51]	giv[51]	_	_
8-29	854-858	with	person[51]	giv[51]	_	_
8-30	859-865	single	person[51]|object[52]	giv[51]|new[52]	_	_
8-31	866-872	tumors	person[51]|object[52]	giv[51]|new[52]	_	_
8-32	873-875	or	person[51]	giv[51]	_	_
8-33	876-888	multinodular	person[51]|object[53]	giv[51]|new[53]	_	_
8-34	889-895	tumors	person[51]|object[53]	giv[51]|new[53]	_	_
8-35	896-900	with	person[51]|object[53]	giv[51]|new[53]	_	_
8-36	901-905	good	person[51]|object[53]|abstract[55]	giv[51]|new[53]|new[55]	_	_
8-37	906-911	liver	person[51]|object[53]|object|abstract[55]	giv[51]|new[53]|giv|new[55]	_	_
8-38	912-919	reserve	person[51]|object[53]|abstract[55]	giv[51]|new[53]|new[55]	_	_
8-39	920-921	.	_	_	_	_

#Text=Chemotherapy is not routinely used due to the chemoresistant character of HCC .
9-1	922-934	Chemotherapy	abstract	new	_	_
9-2	935-937	is	_	_	_	_
9-3	938-941	not	_	_	_	_
9-4	942-951	routinely	_	_	_	_
9-5	952-956	used	_	_	_	_
9-6	957-960	due	_	_	_	_
9-7	961-963	to	_	_	_	_
9-8	964-967	the	abstract[57]	new[57]	_	_
9-9	968-982	chemoresistant	abstract[57]	new[57]	_	_
9-10	983-992	character	abstract[57]	new[57]	_	_
9-11	993-995	of	abstract[57]	new[57]	_	_
9-12	996-999	HCC	abstract[57]|abstract	new[57]|giv	coref	10-2[59_0]
9-13	1000-1001	.	_	_	_	_

#Text=For advanced HCC , sorafenib , a multi-tyrosine kinase inhibitor ( MTKI ) , has been the only approved systemic first-line agent for over a decade , until lenvatinib , another MTKI , recently came into play .
10-1	1002-1005	For	_	_	_	_
10-2	1006-1014	advanced	abstract[59]|abstract[60]	giv[59]|new[60]	ana|coref|ana|coref	11-3[0_60]|12-34[0_59]|11-3[0_60]|12-34[0_59]
10-3	1015-1018	HCC	abstract[59]|abstract[60]	giv[59]|new[60]	_	_
10-4	1019-1020	,	abstract[60]	new[60]	_	_
10-5	1021-1030	sorafenib	abstract[60]|substance	new[60]|new	_	_
10-6	1031-1032	,	_	_	_	_
10-7	1033-1034	a	abstract[63]	new[63]	_	_
10-8	1035-1049	multi-tyrosine	abstract[63]	new[63]	_	_
10-9	1050-1056	kinase	abstract|abstract[63]	new|new[63]	_	_
10-10	1057-1066	inhibitor	abstract[63]	new[63]	_	_
10-11	1067-1068	(	_	_	_	_
10-12	1069-1073	MTKI	object	new	appos	10-31[68_0]
10-13	1074-1075	)	_	_	_	_
10-14	1076-1077	,	_	_	_	_
10-15	1078-1081	has	_	_	_	_
10-16	1082-1086	been	_	_	_	_
10-17	1087-1090	the	person[65]	new[65]	_	_
10-18	1091-1095	only	person[65]	new[65]	_	_
10-19	1096-1104	approved	person[65]	new[65]	_	_
10-20	1105-1113	systemic	person[65]	new[65]	_	_
10-21	1114-1124	first-line	person[65]	new[65]	_	_
10-22	1125-1130	agent	person[65]	new[65]	_	_
10-23	1131-1134	for	person[65]	new[65]	_	_
10-24	1135-1139	over	person[65]	new[65]	_	_
10-25	1140-1141	a	person[65]|time[66]	new[65]|new[66]	_	_
10-26	1142-1148	decade	person[65]|time[66]	new[65]|new[66]	_	_
10-27	1149-1150	,	person[65]	new[65]	_	_
10-28	1151-1156	until	person[65]	new[65]	_	_
10-29	1157-1167	lenvatinib	person[65]|substance	new[65]|new	_	_
10-30	1168-1169	,	_	_	_	_
10-31	1170-1177	another	object[68]	giv[68]	_	_
10-32	1178-1182	MTKI	object[68]	giv[68]	_	_
10-33	1183-1184	,	_	_	_	_
10-34	1185-1193	recently	_	_	_	_
10-35	1194-1198	came	_	_	_	_
10-36	1199-1203	into	_	_	_	_
10-37	1204-1208	play	event	new	_	_
10-38	1209-1210	.	_	_	_	_

#Text=Yet , their clinical efficacy was suboptimal , with only ~3 months of prolonged survival .
11-1	1211-1214	Yet	_	_	_	_
11-2	1215-1216	,	_	_	_	_
11-3	1217-1222	their	abstract|abstract[71]	giv|new[71]	_	_
11-4	1223-1231	clinical	abstract[71]	new[71]	_	_
11-5	1232-1240	efficacy	abstract[71]	new[71]	_	_
11-6	1241-1244	was	_	_	_	_
11-7	1245-1255	suboptimal	_	_	_	_
11-8	1256-1257	,	_	_	_	_
11-9	1258-1262	with	_	_	_	_
11-10	1263-1267	only	time[72]	new[72]	_	_
11-11	1268-1270	~3	time[72]	new[72]	_	_
11-12	1271-1277	months	time[72]	new[72]	_	_
11-13	1278-1280	of	time[72]	new[72]	_	_
11-14	1281-1290	prolonged	time[72]|event[73]	new[72]|giv[73]	coref	13-16[0_73]
11-15	1291-1299	survival	time[72]|event[73]	new[72]|giv[73]	_	_
11-16	1300-1301	.	_	_	_	_

#Text=Second-line treatments include regorafenib and cabozantinib , also MTKIs ; nivolumab and pembrolizumab , immune checkpoint inhibitors targeting programmed death-1 ( PD-1 ) ; and ramucirumab , the first biomarker-driven therapeutics approved for HCC that targets the angiogenic vascular endothelial growth factor receptor ( VEGFR ) , all of which have not been established until the past few years and require further investigations .
12-1	1302-1313	Second-line	abstract[74]	new[74]	_	_
12-2	1314-1324	treatments	abstract[74]	new[74]	_	_
12-3	1325-1332	include	_	_	_	_
12-4	1333-1344	regorafenib	substance	new	_	_
12-5	1345-1348	and	_	_	_	_
12-6	1349-1361	cabozantinib	substance	new	appos	12-9[78_0]
12-7	1362-1363	,	_	_	_	_
12-8	1364-1368	also	_	_	_	_
12-9	1369-1374	MTKIs	object|substance[78]	new|giv[78]	_	_
12-10	1375-1376	;	substance[78]	giv[78]	_	_
12-11	1377-1386	nivolumab	substance[78]	giv[78]	_	_
12-12	1387-1390	and	substance[78]	giv[78]	_	_
12-13	1391-1404	pembrolizumab	substance[78]	giv[78]	_	_
12-14	1405-1406	,	substance[78]	giv[78]	_	_
12-15	1407-1413	immune	substance[78]|abstract[80]	giv[78]|new[80]	_	_
12-16	1414-1424	checkpoint	substance[78]|place|abstract[80]	giv[78]|new|new[80]	_	_
12-17	1425-1435	inhibitors	substance[78]|abstract[80]	giv[78]|new[80]	_	_
12-18	1436-1445	targeting	_	_	_	_
12-19	1446-1456	programmed	abstract[81]	new[81]	appos	12-22[0_81]
12-20	1457-1464	death-1	abstract[81]	new[81]	_	_
12-21	1465-1466	(	_	_	_	_
12-22	1467-1471	PD-1	abstract	giv	_	_
12-23	1472-1473	)	_	_	_	_
12-24	1474-1475	;	_	_	_	_
12-25	1476-1479	and	_	_	_	_
12-26	1480-1491	ramucirumab	substance	new	_	_
12-27	1492-1493	,	_	_	_	_
12-28	1494-1497	the	abstract[84]	new[84]	_	_
12-29	1498-1503	first	abstract[84]	new[84]	_	_
12-30	1504-1520	biomarker-driven	abstract[84]	new[84]	_	_
12-31	1521-1533	therapeutics	abstract[84]	new[84]	_	_
12-32	1534-1542	approved	_	_	_	_
12-33	1543-1546	for	_	_	_	_
12-34	1547-1550	HCC	abstract	giv	ana	12-48
12-35	1551-1555	that	_	_	_	_
12-36	1556-1563	targets	_	_	_	_
12-37	1564-1567	the	substance[88]	new[88]	_	_
12-38	1568-1578	angiogenic	substance[88]	new[88]	_	_
12-39	1579-1587	vascular	substance[88]	new[88]	_	_
12-40	1588-1599	endothelial	substance[88]	new[88]	_	_
12-41	1600-1606	growth	abstract|substance[88]	new|new[88]	coref	16-18
12-42	1607-1613	factor	abstract|substance[88]	new|new[88]	coref	16-17[116_0]
12-43	1614-1622	receptor	substance[88]	new[88]	_	_
12-44	1623-1624	(	_	_	_	_
12-45	1625-1630	VEGFR	object	new	_	_
12-46	1631-1632	)	_	_	_	_
12-47	1633-1634	,	_	_	_	_
12-48	1635-1638	all	abstract	giv	coref	13-7
12-49	1639-1641	of	_	_	_	_
12-50	1642-1647	which	_	_	_	_
12-51	1648-1652	have	_	_	_	_
12-52	1653-1656	not	_	_	_	_
12-53	1657-1661	been	_	_	_	_
12-54	1662-1673	established	_	_	_	_
12-55	1674-1679	until	_	_	_	_
12-56	1680-1683	the	time[91]	new[91]	_	_
12-57	1684-1688	past	time[91]	new[91]	_	_
12-58	1689-1692	few	time[91]	new[91]	_	_
12-59	1693-1698	years	time[91]	new[91]	_	_
12-60	1699-1702	and	_	_	_	_
12-61	1703-1710	require	_	_	_	_
12-62	1711-1718	further	abstract[92]	new[92]	_	_
12-63	1719-1733	investigations	abstract[92]	new[92]	_	_
12-64	1734-1735	.	_	_	_	_

#Text=So far , treatment outcomes for HCC are far from satisfactory , with a 5-year survival rate of only ~18 % .
13-1	1736-1738	So	_	_	_	_
13-2	1739-1742	far	_	_	_	_
13-3	1743-1744	,	_	_	_	_
13-4	1745-1754	treatment	abstract|abstract[94]	new|new[94]	coref|coref	23-12[191_0]|23-12[191_0]
13-5	1755-1763	outcomes	abstract[94]	new[94]	_	_
13-6	1764-1767	for	abstract[94]	new[94]	_	_
13-7	1768-1771	HCC	abstract[94]|abstract	new[94]|giv	coref	14-15
13-8	1772-1775	are	_	_	_	_
13-9	1776-1779	far	_	_	_	_
13-10	1780-1784	from	_	_	_	_
13-11	1785-1797	satisfactory	_	_	_	_
13-12	1798-1799	,	_	_	_	_
13-13	1800-1804	with	_	_	_	_
13-14	1805-1806	a	abstract[97]	new[97]	_	_
13-15	1807-1813	5-year	abstract[97]	new[97]	_	_
13-16	1814-1822	survival	event|abstract[97]	giv|new[97]	_	_
13-17	1823-1827	rate	abstract[97]	new[97]	_	_
13-18	1828-1830	of	abstract[97]	new[97]	_	_
13-19	1831-1835	only	abstract[97]|quantity[98]	new[97]|giv[98]	_	_
13-20	1836-1839	~18	abstract[97]|quantity[98]	new[97]|giv[98]	_	_
13-21	1840-1841	%	abstract[97]|quantity[98]	new[97]|giv[98]	_	_
13-22	1842-1843	.	_	_	_	_

#Text=Evidently , there is an urgent need to develop more effective therapeutic strategies in HCC .
14-1	1844-1853	Evidently	_	_	_	_
14-2	1854-1855	,	_	_	_	_
14-3	1856-1861	there	_	_	_	_
14-4	1862-1864	is	_	_	_	_
14-5	1865-1867	an	abstract[99]	new[99]	_	_
14-6	1868-1874	urgent	abstract[99]	new[99]	_	_
14-7	1875-1879	need	abstract[99]	new[99]	_	_
14-8	1880-1882	to	_	_	_	_
14-9	1883-1890	develop	_	_	_	_
14-10	1891-1895	more	abstract[100]	new[100]	_	_
14-11	1896-1905	effective	abstract[100]	new[100]	_	_
14-12	1906-1917	therapeutic	abstract[100]	new[100]	_	_
14-13	1918-1928	strategies	abstract[100]	new[100]	_	_
14-14	1929-1931	in	abstract[100]	new[100]	_	_
14-15	1932-1935	HCC	abstract[100]|abstract	new[100]|giv	coref	15-20[106_0]
14-16	1936-1937	.	_	_	_	_

#Text=Signal transducer and activator of transcription 3 ( STAT3 ) has recently emerged as a potential therapeutic target for HCC due to its crucial roles in oncogenesis .
15-1	1938-1944	Signal	person[102]	new[102]	_	_
15-2	1945-1955	transducer	person[102]	new[102]	_	_
15-3	1956-1959	and	_	_	_	_
15-4	1960-1969	activator	place[103]	new[103]	_	_
15-5	1970-1972	of	place[103]	new[103]	_	_
15-6	1973-1986	transcription	place[103]|abstract[104]	new[103]|new[104]	_	_
15-7	1987-1988	3	place[103]|abstract[104]	new[103]|new[104]	_	_
15-8	1989-1990	(	place[103]|abstract[104]	new[103]|new[104]	_	_
15-9	1991-1996	STAT3	place[103]|abstract[104]|abstract	new[103]|new[104]|new	coref	16-1
15-10	1997-1998	)	place[103]|abstract[104]	new[103]|new[104]	_	_
15-11	1999-2002	has	_	_	_	_
15-12	2003-2011	recently	_	_	_	_
15-13	2012-2019	emerged	_	_	_	_
15-14	2020-2022	as	_	_	_	_
15-15	2023-2024	a	_	_	_	_
15-16	2025-2034	potential	_	_	_	_
15-17	2035-2046	therapeutic	_	_	_	_
15-18	2047-2053	target	_	_	_	_
15-19	2054-2057	for	_	_	_	_
15-20	2058-2061	HCC	abstract[106]	giv[106]	ana	15-23[0_106]
15-21	2062-2065	due	abstract[106]	giv[106]	_	_
15-22	2066-2068	to	_	_	_	_
15-23	2069-2072	its	abstract|abstract[108]	giv|new[108]	coref|coref|coref|coref	20-13[172_108]|21-8|20-13[172_108]|21-8
15-24	2073-2080	crucial	abstract[108]	new[108]	_	_
15-25	2081-2086	roles	abstract[108]	new[108]	_	_
15-26	2087-2089	in	abstract[108]	new[108]	_	_
15-27	2090-2101	oncogenesis	abstract[108]|abstract	new[108]|new	_	_
15-28	2102-2103	.	_	_	_	_

#Text=STAT3 was initially determined to control acute-phase genes in response to interleukin-6 ( IL-6 ) and epidermal growth factor ( EGF ) during inflammation .
16-1	2104-2109	STAT3	abstract	giv	coref	20-7
16-2	2110-2113	was	_	_	_	_
16-3	2114-2123	initially	_	_	_	_
16-4	2124-2134	determined	_	_	_	_
16-5	2135-2137	to	_	_	_	_
16-6	2138-2145	control	_	_	_	_
16-7	2146-2157	acute-phase	abstract[111]	new[111]	_	_
16-8	2158-2163	genes	abstract[111]	new[111]	_	_
16-9	2164-2166	in	_	_	_	_
16-10	2167-2175	response	abstract	new	_	_
16-11	2176-2178	to	_	_	_	_
16-12	2179-2192	interleukin-6	abstract	new	appos	16-14
16-13	2193-2194	(	_	_	_	_
16-14	2195-2199	IL-6	abstract	giv	_	_
16-15	2200-2201	)	_	_	_	_
16-16	2202-2205	and	_	_	_	_
16-17	2206-2215	epidermal	abstract[116]	giv[116]	appos	16-21[0_116]
16-18	2216-2222	growth	abstract|abstract[116]	giv|giv[116]	coref	20-21
16-19	2223-2229	factor	abstract[116]	giv[116]	_	_
16-20	2230-2231	(	_	_	_	_
16-21	2232-2235	EGF	abstract	giv	_	_
16-22	2236-2237	)	_	_	_	_
16-23	2238-2244	during	_	_	_	_
16-24	2245-2257	inflammation	abstract	new	ana	17-1
16-25	2258-2259	.	_	_	_	_

#Text=It belongs to the STAT family of cytoplasmic transcription factors that mediate signal transduction from the plasma membrane to the nucleus in various cellular activities .
17-1	2260-2262	It	abstract	giv	_	_
17-2	2263-2270	belongs	_	_	_	_
17-3	2271-2273	to	_	_	_	_
17-4	2274-2277	the	abstract[121]	new[121]	coref	18-1[129_121]
17-5	2278-2282	STAT	person|abstract[121]	new|new[121]	_	_
17-6	2283-2289	family	abstract[121]	new[121]	_	_
17-7	2290-2292	of	abstract[121]	new[121]	_	_
17-8	2293-2304	cytoplasmic	abstract[121]|abstract[122]	new[121]|new[122]	_	_
17-9	2305-2318	transcription	abstract[121]|abstract[122]	new[121]|new[122]	_	_
17-10	2319-2326	factors	abstract[121]|abstract[122]	new[121]|new[122]	_	_
17-11	2327-2331	that	_	_	_	_
17-12	2332-2339	mediate	_	_	_	_
17-13	2340-2346	signal	abstract|event[124]	new|new[124]	_	_
17-14	2347-2359	transduction	event[124]	new[124]	_	_
17-15	2360-2364	from	_	_	_	_
17-16	2365-2368	the	place[126]	new[126]	_	_
17-17	2369-2375	plasma	abstract|place[126]	new|new[126]	_	_
17-18	2376-2384	membrane	place[126]	new[126]	_	_
17-19	2385-2387	to	place[126]	new[126]	_	_
17-20	2388-2391	the	place[126]|place[127]	new[126]|new[127]	_	_
17-21	2392-2399	nucleus	place[126]|place[127]	new[126]|new[127]	_	_
17-22	2400-2402	in	place[126]|place[127]	new[126]|new[127]	_	_
17-23	2403-2410	various	place[126]|place[127]|abstract[128]	new[126]|new[127]|new[128]	_	_
17-24	2411-2419	cellular	place[126]|place[127]|abstract[128]	new[126]|new[127]|new[128]	_	_
17-25	2420-2430	activities	place[126]|place[127]|abstract[128]	new[126]|new[127]|new[128]	_	_
17-26	2431-2432	.	_	_	_	_

#Text=The STAT family comprises seven members : STAT1 , 2 , 3 , 4 , 5a , 5b and 6 .
18-1	2433-2436	The	abstract[129]	giv[129]	ana	19-7[0_129]
18-2	2437-2441	STAT	abstract[129]	giv[129]	_	_
18-3	2442-2448	family	abstract[129]	giv[129]	_	_
18-4	2449-2458	comprises	_	_	_	_
18-5	2459-2464	seven	abstract[130]	new[130]	ana	19-3[0_130]
18-6	2465-2472	members	abstract[130]	new[130]	_	_
18-7	2473-2474	:	_	_	_	_
18-8	2475-2480	STAT1	abstract[131]	new[131]	ana	19-1[133_131]
18-9	2481-2482	,	abstract[131]	new[131]	_	_
18-10	2483-2484	2	abstract[131]	new[131]	_	_
18-11	2485-2486	,	_	_	_	_
18-12	2487-2488	3	_	_	_	_
18-13	2489-2490	,	_	_	_	_
18-14	2491-2492	4	quantity	new	_	_
18-15	2493-2494	,	_	_	_	_
18-16	2495-2497	5a	_	_	_	_
18-17	2498-2499	,	_	_	_	_
18-18	2500-2502	5b	_	_	_	_
18-19	2503-2506	and	_	_	_	_
18-20	2507-2508	6	_	_	_	_
18-21	2509-2510	.	_	_	_	_

#Text=Each of them consists of ( i ) an N-terminal domain for oligomerization , ( ii ) a coiled-coil domain for interaction with regulatory proteins , ( iii ) a DNA-binding domain for recognition of specific DNA sequences , ( iv ) a Src homology-2 ( SH2 ) domain that triggers phosphorylation and dimerization after docking to phosphorylated receptors and ( iv ) a C-terminal transactivation domain with specific tyrosine ( Y ) ( present in all STATs ) and serine ( S ) residues ( absent in STAT2 and 6 ) that are phosphorylated upon transcriptional activation .
19-1	2511-2515	Each	abstract[133]	giv[133]	_	_
19-2	2516-2518	of	abstract[133]	giv[133]	_	_
19-3	2519-2523	them	abstract[133]|abstract	giv[133]|giv	_	_
19-4	2524-2532	consists	_	_	_	_
19-5	2533-2535	of	_	_	_	_
19-6	2536-2537	(	_	_	_	_
19-7	2538-2539	i	abstract	giv	_	_
19-8	2540-2541	)	_	_	_	_
19-9	2542-2544	an	place[136]	new[136]	coref	19-30[143_136]
19-10	2545-2555	N-terminal	place[136]	new[136]	_	_
19-11	2556-2562	domain	place[136]	new[136]	_	_
19-12	2563-2566	for	place[136]	new[136]	_	_
19-13	2567-2582	oligomerization	place[136]|abstract	new[136]|new	appos	19-16
19-14	2583-2584	,	_	_	_	_
19-15	2585-2586	(	_	_	_	_
19-16	2587-2589	ii	abstract	giv	_	_
19-17	2590-2591	)	_	_	_	_
19-18	2592-2593	a	place[139]	new[139]	_	_
19-19	2594-2605	coiled-coil	place[139]	new[139]	_	_
19-20	2606-2612	domain	place[139]	new[139]	_	_
19-21	2613-2616	for	place[139]	new[139]	_	_
19-22	2617-2628	interaction	place[139]|abstract[140]	new[139]|new[140]	_	_
19-23	2629-2633	with	place[139]|abstract[140]	new[139]|new[140]	_	_
19-24	2634-2644	regulatory	place[139]|abstract[140]|abstract[141]	new[139]|new[140]|new[141]	appos	19-28[0_141]
19-25	2645-2653	proteins	place[139]|abstract[140]|abstract[141]	new[139]|new[140]|new[141]	_	_
19-26	2654-2655	,	place[139]|abstract[140]	new[139]|new[140]	_	_
19-27	2656-2657	(	place[139]|abstract[140]	new[139]|new[140]	_	_
19-28	2658-2661	iii	place[139]|abstract[140]|abstract	new[139]|new[140]|giv	_	_
19-29	2662-2663	)	place[139]|abstract[140]	new[139]|new[140]	_	_
19-30	2664-2665	a	place[139]|abstract[140]|place[143]	new[139]|new[140]|giv[143]	coref	19-49[0_143]
19-31	2666-2677	DNA-binding	place[139]|abstract[140]|place[143]	new[139]|new[140]|giv[143]	_	_
19-32	2678-2684	domain	place[139]|abstract[140]|place[143]	new[139]|new[140]|giv[143]	_	_
19-33	2685-2688	for	place[139]|abstract[140]|place[143]	new[139]|new[140]|giv[143]	_	_
19-34	2689-2700	recognition	place[139]|abstract[140]|place[143]|event[144]	new[139]|new[140]|giv[143]|new[144]	_	_
19-35	2701-2703	of	place[139]|abstract[140]|place[143]|event[144]	new[139]|new[140]|giv[143]|new[144]	_	_
19-36	2704-2712	specific	place[139]|abstract[140]|place[143]|event[144]|abstract[146]	new[139]|new[140]|giv[143]|new[144]|new[146]	_	_
19-37	2713-2716	DNA	place[139]|abstract[140]|place[143]|event[144]|abstract|abstract[146]	new[139]|new[140]|giv[143]|new[144]|new|new[146]	_	_
19-38	2717-2726	sequences	place[139]|abstract[140]|place[143]|event[144]|abstract[146]	new[139]|new[140]|giv[143]|new[144]|new[146]	_	_
19-39	2727-2728	,	_	_	_	_
19-40	2729-2730	(	_	_	_	_
19-41	2731-2733	iv	person	new	appos	19-62
19-42	2734-2735	)	_	_	_	_
19-43	2736-2737	a	abstract[149]	new[149]	appos	19-47[0_149]
19-44	2738-2741	Src	abstract|abstract[149]	new|new[149]	_	_
19-45	2742-2752	homology-2	abstract[149]	new[149]	_	_
19-46	2753-2754	(	_	_	_	_
19-47	2755-2758	SH2	abstract	giv	_	_
19-48	2759-2760	)	_	_	_	_
19-49	2761-2767	domain	place	giv	coref	19-64[157_0]
19-50	2768-2772	that	_	_	_	_
19-51	2773-2781	triggers	_	_	_	_
19-52	2782-2797	phosphorylation	event	new	_	_
19-53	2798-2801	and	_	_	_	_
19-54	2802-2814	dimerization	event	new	_	_
19-55	2815-2820	after	_	_	_	_
19-56	2821-2828	docking	_	_	_	_
19-57	2829-2831	to	_	_	_	_
19-58	2832-2846	phosphorylated	substance[154]	new[154]	_	_
19-59	2847-2856	receptors	substance[154]	new[154]	_	_
19-60	2857-2860	and	_	_	_	_
19-61	2861-2862	(	_	_	_	_
19-62	2863-2865	iv	person	giv	_	_
19-63	2866-2867	)	_	_	_	_
19-64	2868-2869	a	place[157]	giv[157]	_	_
19-65	2870-2880	C-terminal	place[157]	giv[157]	_	_
19-66	2881-2896	transactivation	abstract|place[157]	new|giv[157]	_	_
19-67	2897-2903	domain	place[157]	giv[157]	_	_
19-68	2904-2908	with	place[157]	giv[157]	_	_
19-69	2909-2917	specific	place[157]|abstract[158]	giv[157]|new[158]	appos	19-72[0_158]
19-70	2918-2926	tyrosine	place[157]|abstract[158]	giv[157]|new[158]	_	_
19-71	2927-2928	(	place[157]	giv[157]	_	_
19-72	2929-2930	Y	place[157]|abstract	giv[157]|giv	_	_
19-73	2931-2932	)	place[157]	giv[157]	_	_
19-74	2933-2934	(	place[157]	giv[157]	_	_
19-75	2935-2942	present	place[157]	giv[157]	_	_
19-76	2943-2945	in	place[157]	giv[157]	_	_
19-77	2946-2949	all	place[157]|object[160]	giv[157]|new[160]	_	_
19-78	2950-2955	STATs	place[157]|object[160]	giv[157]|new[160]	_	_
19-79	2956-2957	)	place[157]	giv[157]	_	_
19-80	2958-2961	and	place[157]	giv[157]	_	_
19-81	2962-2968	serine	place[157]|substance|abstract[163]	giv[157]|new|new[163]	_	_
19-82	2969-2970	(	place[157]|abstract[163]	giv[157]|new[163]	_	_
19-83	2971-2972	S	place[157]|person|abstract[163]	giv[157]|new|new[163]	_	_
19-84	2973-2974	)	place[157]|abstract[163]	giv[157]|new[163]	_	_
19-85	2975-2983	residues	place[157]|abstract[163]	giv[157]|new[163]	_	_
19-86	2984-2985	(	_	_	_	_
19-87	2986-2992	absent	_	_	_	_
19-88	2993-2995	in	_	_	_	_
19-89	2996-3001	STAT2	abstract	new	_	_
19-90	3002-3005	and	_	_	_	_
19-91	3006-3007	6	quantity	new	_	_
19-92	3008-3009	)	_	_	_	_
19-93	3010-3014	that	_	_	_	_
19-94	3015-3018	are	_	_	_	_
19-95	3019-3033	phosphorylated	_	_	_	_
19-96	3034-3038	upon	_	_	_	_
19-97	3039-3054	transcriptional	event[166]	new[166]	_	_
19-98	3055-3065	activation	event[166]	new[166]	_	_
19-99	3066-3067	.	_	_	_	_

#Text=Intensive investigation has been done on STAT3 since its discovery , revealing its physiological roles in early embryonic development , growth and differentiation of various adult tissues .
20-1	3068-3077	Intensive	abstract[167]	new[167]	_	_
20-2	3078-3091	investigation	abstract[167]	new[167]	_	_
20-3	3092-3095	has	_	_	_	_
20-4	3096-3100	been	_	_	_	_
20-5	3101-3105	done	_	_	_	_
20-6	3106-3108	on	_	_	_	_
20-7	3109-3114	STAT3	abstract	giv	ana	20-9
20-8	3115-3120	since	_	_	_	_
20-9	3121-3124	its	abstract|abstract[170]	giv|new[170]	ana|ana	20-13|20-13
20-10	3125-3134	discovery	abstract[170]	new[170]	_	_
20-11	3135-3136	,	_	_	_	_
20-12	3137-3146	revealing	_	_	_	_
20-13	3147-3150	its	abstract|abstract[172]	giv|giv[172]	coref|coref|coref|coref	21-4[178_172]|22-4|21-4[178_172]|22-4
20-14	3151-3164	physiological	abstract[172]	giv[172]	_	_
20-15	3165-3170	roles	abstract[172]	giv[172]	_	_
20-16	3171-3173	in	_	_	_	_
20-17	3174-3179	early	abstract[173]	new[173]	coref	24-15[197_173]
20-18	3180-3189	embryonic	abstract[173]	new[173]	_	_
20-19	3190-3201	development	abstract[173]	new[173]	_	_
20-20	3202-3203	,	_	_	_	_
20-21	3204-3210	growth	event	giv	ana	21-4
20-22	3211-3214	and	_	_	_	_
20-23	3215-3230	differentiation	event[175]	new[175]	_	_
20-24	3231-3233	of	event[175]	new[175]	_	_
20-25	3234-3241	various	event[175]|object[176]	new[175]|new[176]	_	_
20-26	3242-3247	adult	event[175]|object[176]	new[175]|new[176]	_	_
20-27	3248-3255	tissues	event[175]|object[176]	new[175]|new[176]	_	_
20-28	3256-3257	.	_	_	_	_

#Text=In addition , its pathogenic roles in cancer initiation , progression , metastasis , chemoresistance and immunoevasion have been uncovered .
21-1	3258-3260	In	_	_	_	_
21-2	3261-3269	addition	_	_	_	_
21-3	3270-3271	,	_	_	_	_
21-4	3272-3275	its	event|abstract[178]	giv|giv[178]	coref|coref	24-7[194_178]|24-7[194_178]
21-5	3276-3286	pathogenic	abstract[178]	giv[178]	_	_
21-6	3287-3292	roles	abstract[178]	giv[178]	_	_
21-7	3293-3295	in	abstract[178]	giv[178]	_	_
21-8	3296-3302	cancer	abstract[178]|abstract|abstract[180]	giv[178]|giv|new[180]	coref|coref	23-12|23-12
21-9	3303-3313	initiation	abstract[178]|abstract[180]	giv[178]|new[180]	_	_
21-10	3314-3315	,	abstract[178]	giv[178]	_	_
21-11	3316-3327	progression	abstract[178]|event	giv[178]|new	_	_
21-12	3328-3329	,	abstract[178]	giv[178]	_	_
21-13	3330-3340	metastasis	abstract[178]|abstract	giv[178]|new	_	_
21-14	3341-3342	,	abstract[178]	giv[178]	_	_
21-15	3343-3358	chemoresistance	abstract[178]|abstract	giv[178]|new	_	_
21-16	3359-3362	and	abstract[178]	giv[178]	_	_
21-17	3363-3376	immunoevasion	abstract[178]|abstract	giv[178]|new	_	_
21-18	3377-3381	have	_	_	_	_
21-19	3382-3386	been	_	_	_	_
21-20	3387-3396	uncovered	_	_	_	_
21-21	3397-3398	.	_	_	_	_

#Text=To date , STAT3 is widely recognized as an oncogenic factor in diverse human cancers .
22-1	3399-3401	To	_	_	_	_
22-2	3402-3406	date	time	new	_	_
22-3	3407-3408	,	_	_	_	_
22-4	3409-3414	STAT3	abstract	giv	coref	23-4
22-5	3415-3417	is	_	_	_	_
22-6	3418-3424	widely	_	_	_	_
22-7	3425-3435	recognized	_	_	_	_
22-8	3436-3438	as	_	_	_	_
22-9	3439-3441	an	_	_	_	_
22-10	3442-3451	oncogenic	_	_	_	_
22-11	3452-3458	factor	_	_	_	_
22-12	3459-3461	in	_	_	_	_
22-13	3462-3469	diverse	abstract[187]	new[187]	_	_
22-14	3470-3475	human	abstract[187]	new[187]	_	_
22-15	3476-3483	cancers	abstract[187]	new[187]	_	_
22-16	3484-3485	.	_	_	_	_

#Text=Therefore , targeting STAT3 might be an attractive therapeutic strategy for HCC treatment .
23-1	3486-3495	Therefore	_	_	_	_
23-2	3496-3497	,	_	_	_	_
23-3	3498-3507	targeting	_	_	_	_
23-4	3508-3513	STAT3	abstract	giv	coref	24-11[195_0]
23-5	3514-3519	might	_	_	_	_
23-6	3520-3522	be	_	_	_	_
23-7	3523-3525	an	abstract[189]	new[189]	_	_
23-8	3526-3536	attractive	abstract[189]	new[189]	_	_
23-9	3537-3548	therapeutic	abstract[189]	new[189]	_	_
23-10	3549-3557	strategy	abstract[189]	new[189]	_	_
23-11	3558-3561	for	abstract[189]	new[189]	_	_
23-12	3562-3565	HCC	abstract[189]|abstract|abstract[191]	new[189]|giv|giv[191]	coref|coref	24-13|24-13
23-13	3566-3575	treatment	abstract[189]|abstract[191]	new[189]|giv[191]	_	_
23-14	3576-3577	.	_	_	_	_

#Text=In this review , we summarize the oncogenic roles of STAT3 in HCC and the current clinical development of STAT3-targeted therapeutics .
24-1	3578-3580	In	_	_	_	_
24-2	3581-3585	this	abstract[192]	new[192]	_	_
24-3	3586-3592	review	abstract[192]	new[192]	_	_
24-4	3593-3594	,	_	_	_	_
24-5	3595-3597	we	person	acc	_	_
24-6	3598-3607	summarize	_	_	_	_
24-7	3608-3611	the	abstract[194]	giv[194]	_	_
24-8	3612-3621	oncogenic	abstract[194]	giv[194]	_	_
24-9	3622-3627	roles	abstract[194]	giv[194]	_	_
24-10	3628-3630	of	abstract[194]	giv[194]	_	_
24-11	3631-3636	STAT3	abstract[194]|abstract[195]	giv[194]|giv[195]	_	_
24-12	3637-3639	in	abstract[194]|abstract[195]	giv[194]|giv[195]	_	_
24-13	3640-3643	HCC	abstract[194]|abstract[195]|object	giv[194]|giv[195]|giv	_	_
24-14	3644-3647	and	abstract[194]	giv[194]	_	_
24-15	3648-3651	the	abstract[194]|abstract[197]	giv[194]|giv[197]	_	_
24-16	3652-3659	current	abstract[194]|abstract[197]	giv[194]|giv[197]	_	_
24-17	3660-3668	clinical	abstract[194]|abstract[197]	giv[194]|giv[197]	_	_
24-18	3669-3680	development	abstract[194]|abstract[197]	giv[194]|giv[197]	_	_
24-19	3681-3683	of	abstract[194]|abstract[197]	giv[194]|giv[197]	_	_
24-20	3684-3698	STAT3-targeted	abstract[194]|abstract[197]|event|abstract[199]	giv[194]|giv[197]|new|new[199]	_	_
24-21	3699-3711	therapeutics	abstract[194]|abstract[197]|abstract[199]	giv[194]|giv[197]|new[199]	_	_
24-22	3712-3713	.	_	_	_	_
